IMNM Immunome, Inc.

NASDAQ
$21.41

Immunome, Inc. (IMNM) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.64 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -15.1% since its last earnings release on August 11, 2026.

Immunome Missed Consensus Estimates
Tuesday, August 11, 2026 · 4:02 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.64)
Rev est $2M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $25.97

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Immunome, Inc.

Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.